Profound Medical Corp. and Philips Sign Sales and Marketing Agreement in MRI-guided therapy for prostate cancer care
11 Maio 2016 - 08:10AM
Profound Medical Corp. (TSXV:PRN), a Toronto-based medical device
company and Royal Philips (NYSE:PHG) (AEX:PHIA), a leading health
technology company, today announced that they have signed a sales
and marketing agreement that will advance the commercial launch of
Profound’s TULSA-PROTM, a minimally invasive system to ablate
targeted prostate tissue.
Under the terms of the agreement, the two companies will
collaborate in the commercialization of TULSA-PRO in Europe
followed by Canada, the U.S. and other markets, subject to
regulatory clearance in those jurisdictions.
TULSA (Transurethral Ultrasound Ablation) technology combines
real-time Magnetic Resonance (MR) imaging with transurethral
therapeutic, robotically-driven ultrasound and closed-loop thermal
feedback control providing a highly precise treatment tailored to
patient-specific anatomy and pathology. The agreement follows a
previously established collaboration to support Profound’s
proprietary technology on Philips’ Ingenia and Achieva 3T MRI
platforms.
“Our agreement with Philips will enable us to increase our reach
of this unique technology to more clinicians and their patients
requiring prostate care,” said Steve Plymale, CEO, Profound Medical
Corp. “I am convinced that our TULSA technology will be a valuable
addition to Philips’ expanding interventional oncology
portfolio.”
“Magnetic Resonance Imaging or MRI is emerging as a powerful
tool in oncology,” said Christopher Busch, General Manager MR
Therapy at Philips. “For example, MRI has an essential role to play
in the diagnosis, treatment and monitoring of prostate cancer. Our
collaboration with Profound Medical in MRI-guided therapy further
extends our portfolio of treatment technologies that we can offer
to advance prostate cancer care.”
TULSA-PRO for MRI-guided treatment of the prostate gland will
complement Philips’ 3T MRI for multi-parametric diagnostic imaging
of the prostate, image-guided biopsies (MRI guided or ultrasound
guided with MR registration), and MRI-only simulation for radiation
therapy treatment planning, covering the various stages of prostate
cancer care.
About Profound Medical Corp.Profound Medical is
a Canadian medical device company that has developed a unique and
minimally invasive treatment to ablate the prostate gland in
prostate cancer patients. Profound’s novel technology combines
real-time MR imaging with transurethral therapeutic,
robotically-driven ultrasound and closed-loop thermal feedback
control. It provides a highly precise treatment tailored to
patient-specific anatomy and pathology. This method of prostate
ablation offers short treatment times and low morbidity, allowing
for fast patient recovery. For more information, visit
profoundmedical.com
About Royal Philips Royal Philips (NYSE:PHG)
(AEX:PHIA) is a leading health technology company focused on
improving people’s health and enabling better outcomes across the
health continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. The company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips’ wholly owned
subsidiary Philips Lighting is the global leader in lighting
products, systems and services. Headquartered in the Netherlands,
Philips posted 2015 sales of EUR 24.2 billion and employs
approximately 104,000 employees with sales and services in more
than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding
Profound and its business which may include, but is not limited to,
the expectations regarding the efficacy of Profound’s technology in
the treatment of prostate cancer. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of each
entity. The forward-looking events and circumstances discussed in
this release, may not occur by certain specified dates or at all
and could differ materially as a result of known and unknown risk
factors and uncertainties affecting the company, including risks
regarding the pharmaceutical industry, economic factors, the equity
markets generally and risks associated with growth and
competition. Although Profound has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. No forward-looking statement can be
guaranteed. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made and Profound undertakes no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events, or otherwise, other than as required by
law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
For further information, please contact:
Profound Medical
Rebecca von Goetz
Profound Medical Corp.
Tel.: +1 647 476 1350, Ext. 426
Mobile: +1 417 917 8650
E-mail: rvongoetz@profoundmedical.com
Philips
Steve Klink
Philips Group Communications
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com
Koninklijke Philips NV (EU:PHIA)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Koninklijke Philips NV (EU:PHIA)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024